*
homeProductPipeline-BiosimilarOmalizumab

Omalizumab

Omalizumab, a humanized monoclonal antibody IgG1 targeted human IgE. Via binding IgE, omalizumab down regulated the release of antihistamines, leucotrienes, cytokines and other factors, which are triggered by IgE’s binding to FcεRI, and further decreased the symptoms of allergic asthma and chronic idiopathic urticaria.

Omalizumab is the biosimilar versionof Xolair®, and is indicated for allergic asthma and chronic idiopathic urticaria.



scroll to Top